- Home
- CDNA vs SNDX Comparison
CDNA vs SNDX Comparison
Compare CDNA & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDNA
- SNDX
- Stock Information
- Founded
- CDNA 1998
- SNDX 2005
- Country
- CDNA United States
- SNDX United States
- Employees
- CDNA N/A
- SNDX N/A
- Industry
- CDNA Medical Specialities
- SNDX Biotechnology: Pharmaceutical Preparations
- Sector
- CDNA Health Care
- SNDX Health Care
- Exchange
- CDNA Nasdaq
- SNDX Nasdaq
- Market Cap
- CDNA 1.0B
- SNDX 1.1B
- IPO Year
- CDNA 2014
- SNDX 2016
- Fundamental
- Price
- CDNA $19.07
- SNDX $9.12
- Analyst Decision
- CDNA Buy
- SNDX Strong Buy
- Analyst Count
- CDNA 6
- SNDX 11
- Target Price
- CDNA $30.33
- SNDX $35.91
- AVG Volume (30 Days)
- CDNA 989.3K
- SNDX 1.8M
- Earning Date
- CDNA 07-30-2025
- SNDX 07-31-2025
- Dividend Yield
- CDNA N/A
- SNDX N/A
- EPS Growth
- CDNA N/A
- SNDX N/A
- EPS
- CDNA 1.07
- SNDX N/A
- Revenue
- CDNA $346,421,000.00
- SNDX $43,722,000.00
- Revenue This Year
- CDNA $13.31
- SNDX $426.77
- Revenue Next Year
- CDNA $15.46
- SNDX $98.31
- P/E Ratio
- CDNA $17.90
- SNDX N/A
- Revenue Growth
- CDNA 25.92
- SNDX N/A
- 52 Week Low
- CDNA $14.09
- SNDX $8.58
- 52 Week High
- CDNA $34.84
- SNDX $25.07
- Technical
- Relative Strength Index (RSI)
- CDNA 57.48
- SNDX 38.53
- Support Level
- CDNA $18.64
- SNDX $11.00
- Resistance Level
- CDNA $19.44
- SNDX $11.83
- Average True Range (ATR)
- CDNA 0.75
- SNDX 0.54
- MACD
- CDNA -0.05
- SNDX -0.12
- Stochastic Oscillator
- CDNA 46.86
- SNDX 18.12
About CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.